Authors: Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Lu S et al. doi: https://doi.org/10.1101/2022.06.21.22276660 Abstract Epstein-Barr virus (EBV) reactivation has been proposed as a driver of Long COVID (LC), but studies in well- characterized post-acute COVID-19 cohorts of individuals with and without Long COVID symptoms over a time course consistent with current [...]

Authors: Verma D, Thompson J, Swaminathan S PMID: 26976570 PMCID: PMC4822607 DOI: 10.1073/pnas.1523686113 Abstract Clinically available drugs active against Epstein-Barr virus (EBV) and other human herpesviruses are limited to those targeting viral DNA replication. To identify compounds directed against other steps in the viral life cycle, we searched for drugs active against the EBV SM [...]

Authors: Gorres KL, Daigle D, Mohanram S, Mcinerney GE, Lyons DE PMID: 26933051 PMCID: PMC4810481 DOI: 10.1128/mBio.00113-16 Abstract Reactivation of Epstein-Barr virus (EBV) from latency into the lytic phase of its life cycle allows the virus to spread among cells and between hosts. Valproic acid (VPA) inhibits initiation of the lytic cycle in EBV-infected B [...]